IPRP expands and all EU Member States now included in EU-US MRA

Home/Policies & Legislation | Posted 16/08/2019 post-comment0 Post your comment

During the June 2019 International Pharmaceutical Regulators Programme (IPRP) management committee meeting in Amsterdam, The Netherlands, it was announced that Iran’s National Regulatory Authority (NRA) and Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT – Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) have joined the IPRP. There are now 26 members of IPRP. 

Regulation V13H16

The meeting saw Dr Junko Sato of Japan’s Ministry of Health, Labour and Welfare and Ms Hacer Coşkun Çetintaş from the Turkish Medicines and Medical Devices Agency (TİTCK) be elected as chair and vice chair of the management committee. In addition, there were discussions about generics and biosimilars, and regulatory frameworks.

In July 2019, the US Food and Drug Administration (FDA) and the European Union (EU) announced that they have now fully implemented the mutual recognition agreement (MRA) for inspections of manufacturing sites for certain human medicines in their territories. Following FDA assessment, Slovakia was the final EU Member State to be included in the agreement.

The agreement to recognize good manufacturing practice (GMP) inspections of pharmaceutical manufacturing sites conducted in Europe and the US was initially announced in March 2017 [1]. However, at this time not all EU Member States had been assessed by FDA. Now that all EU Member States have been included, the agreement ensures that authorities in the US and across the EU can rely on each other’s inspection results for human medicines and avoid duplicating inspections. Patients can be assured that they can rely on the quality, safety and efficacy of all medicines, no matter where they have been manufactured.

A batch testing waiver will now also apply. Here, EU pharmaceutical companies will no longer have to carry out quality controls for US products when these controls have already been carried out in the US. In the future, the MRA is likely to expand to veterinary medicines, human vaccines and plasma-derived medicinal products.

Related articles
The role of the IPRF in transparency for biosimilars

IPRF issues draft reflection paper for biosimilars extrapolation

1. GaBI Online - Generics and Biosimilars Initiative. EMA and FDA to recognize GMP inspections [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 16]. Available from: www.gabionline.net/Policies-Legislation/EMA-and-FDA-to-recognize-GMP-inspections

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010